BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout
Biohaven Ltd. (BHVN) shares rose 13% after licensing its epilepsy drug program to SK Biopharmaceuticals for up to $795M plus royalties. The deal includes $400M upfront, with Biohaven retaining royalties. SK aims to launch the drug in the U.S. by 2029. Biohaven plans to focus on other pipeline drugs, including obesity and immunology treatments. Raymond James cut its price target to $30 but maintains a 'Strong Buy' rating.
How this was made
The 30-second read
Why it matters
The licensing agreement provides immediate cash and reduces dilution risk, likely supporting the stock's momentum.
Market read
A major licensing deal that injects substantial non‑dilutive capital into Biohaven, driving a sharp price increase and setting a precedent for similar biotech collaborations.
What to watch
Antitrust clearance in the U.S. remains pending, and the royalty structure depends on commercial success of opakalim.
Background
Biohaven (BHVN) is a U.S. biotech focused on neurology and immunology, with several late‑stage programs.
Ticker impact
Biohaven announced a licensing deal with SK Biopharmaceuticals worth up to $795 million, triggering a 13% stock jump.
Expect continued upside as the market prices in reduced dilution risk and potential royalty stream.
Large cash infusion and royalty upside for a biotech with multiple late‑stage programs; the move already drove a double‑digit price gain.
Market effects
Other neuro‑pharma and epilepsy‑focused companies may see relative valuation pressure as capital becomes available to Biohaven.
South Korean biotech sector gains visibility from the partnership with SK Biopharmaceuticals.
The sizable licensing deal highlights continued investor appetite for biotech collaborations, potentially influencing broader biotech M&A activity.
Counterpoint
The deal hinges on future regulatory approval and market uptake; delays could erode the perceived upside.
Key entities
- companyBiohaven Ltd.
U.S. biotech receiving licensing payment.
- companySK Biopharmaceuticals
South Korean partner acquiring worldwide rights to the epilepsy program.
